ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMA.

Autor:	Westin, J., Jacobson, C. A., Chavez, J. C., Sureda, A., Morschhauser, F., Glaß, B., Dickinson, M., Davies, A., Flinn, I. W., Maloney, D. G., Chamuleau, M., Tees, M., Xue, A., Shahani, S., Nikolajeva, O., Kang, J., Kaplan, A., Schupp, M., Miao, H., Rich, E. S.
Předmět:	DIFFUSE large B-cell lymphomas NURSING consultants MUCOSA-associated lymphoid tissue lymphoma LYMPHOMAS CYTOKINE release syndrome
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p171-173, 3p
Abstrakt:	B Methods: b The Phase 3 trial design will enroll 300 adult patients with high-risk, histologically confirmed LBCL based on the 2016 WHO classification, including diffuse large B-cell lymphoma, HGBL, and transformed follicular or marginal zone lymphoma (Swerdlow SH, et al. I Blood i . 2016). B Introduction: b The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) and DA-EPOCH-R (dose-adjusted etoposide [DA-E]), have poor prognoses. ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text